Rapid test plus targeted antibiotic shows promise for tough infections in blood cancer patients

NCT ID NCT04673175

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether the antibiotic ceftolozane-tazobactam, guided by a rapid molecular test, could effectively treat serious Pseudomonas aeruginosa infections in people with blood cancers or those who had a stem cell transplant. The 17 participants received the antibiotic through a vein for 10 to 14 days. The study was terminated early, so results are limited, but researchers aimed to see if patients were alive and infection-free 30 days later.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ceftolozane-tazobactam (Zerbaxa), an antibiotic given through a vein
What this could lead to
If successful, this could show that using a rapid test to quickly match the right antibiotic improves survival and recovery for vulnerable patients with blood cancers.
What could go wrong
The study was terminated early with only 17 participants, so it cannot provide strong evidence. The historical control group also limits how much we can trust the results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTEREMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Weill Cornell Medicine

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.